Clinical trials: Diabetes Mellitus Type 2 With Proteinuria
Diabetic Nephropathy
Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria
Study of the efficacy and safety of aliskiren when added to losartan and optimal antihypertensive therapy in patients with hypertension, type 2 diabetes, and kidney disorders to monitor improvement in any of these conditions.
- Trial name
- NCT00097955
- Testing
- aliskiren
- Where
- 12 sites in United States, Canada and 10 more
- Volunteers
- 496 people
- Sponsor
- Novartis Pharmaceuticals
Cardiovascular Disease
Renal Insufficiency And Cardiovascular Events
Reduced glomerular filtration rate (GFR) has been recently shown to be a powerful predictor of cardiovascular morbidity and mortality in the general population, independent of traditional cardiovascular risk factors.
- Trial name
- RIACE (NCT00715481)
- Where
- 20 sites in Italy
- Volunteers
- 15,628 people
- Sponsor
- Diabetic Nephropathy Study Group
Type 2 Diabetic Nephropathy
Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy
The investigators hypothesize that, LPD supplemented with ketoanalogs will reduce urine podocyte loss and lower the angiotensinogen level in the urine.
- Trial name
- NCT01300273
- Testing
- Compound α-Ketoacid Tablet
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Type 2 Diabetes Mellitus, Diabetic Nephropathy
Effects of Spironolactone Combination Therapy on Proteinuria, Kidney Function, and Blood Pressure
The detrimental effects of aldostrone are not adequately arrested by the use of angiotensin converting enzyme (ACE), angiotensin II receptor blocker (ARB) or a combination of both.
- Conditions
- Type 2 Diabetes Mellitus, Diabetic Nephropathy, Essential Hypertension
- Trial name
- NCT01667614
- Testing
- spironolacone 25 mg tablets added to losartan
- Where
- Iran
- Volunteers
- 136 people
- Sponsor
- Tehran University of Medical Sciences
Diabetic Nephropathy, Nephrotic Syndrome
Adrenocorticotropic Hormone (ACTH) Treatment of Nephrotic Range Proteinuria in Diabetic Nephropathy (NRDN)
This is a prospective open labeled trial examining the efficacy of ACTHar Gel (porcine ACTH) on the level of proteinuria in patients with diabetic nephropathy and nephrotic range proteinuria.
- Trial name
- ACTH-NRDN (NCT01028287)
- Testing
- ACTH
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Southeast Renal Research Institute
Diabetic Nephropathy
A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy
The study hypothesis under test is that administration of a CCR2/5 antagonist to subjects with type 2 diabetes and overt nephropathy will result in a reduction in urinary albumin, a surrogate for improved glomerular filtration.
- Trial name
- NCT01712061
- Testing
- PF-04634817
- Where
- 142 sites in United States, Argentina and 12 more
- Volunteers
- 226 people
- Sponsor
- Pfizer
Diabetic Kidney Disease
SER150 vs Placebo in Diabetic Kidney Disease
This study is to assess the efficacy and safety of SER150 administered for 24 weeks as a 15 mg twice a day BID dose (except on Day 168 15 mg QD) in participants with type 2 diabetes (T2D) and albuminuria in treatment with either…
- Trial name
- NCT04881123
- Testing
- SER150
- Where
- 12 sites in Australia, New Zealand
- Volunteers
- 20 people
- Sponsor
- Serodus AS
Hypertension
Valsartan/Hydrochlorothiazide Combination vs Amlodipine in Patients With Hypertension, Diabetes, and Albuminuria.
The purpose of this study is assess if treatment with valsartan and a diuretic, hydrochlorothiazide, has beneficial effects in people with high blood pressure, diabetes, and albuminuria (protein in the urine) compared with…
- Trial name
- NCT00171561
- Testing
- valsartan/hydrochlorothiazide
- Where
- Switzerland
- Volunteers
- 144 people
- Sponsor
- Novartis
Microalbuminuria, Macroalbuminuric Diabetic Nephropathy
Triple Blockade of the Renin Angiotensin Aldosterone System in Diabetic (Type 1&2) Proteinuric Patients
Study Hypothesis: Reduction in albuminuria has been shown to decrease progression of diabetic nephropathy. In diabetic nephropathy patients treated with maximal antihypertensive doses with dual RAAS blockade (total daily dose…
- Conditions
- Microalbuminuria, Macroalbuminuric Diabetic Nephropathy, Diabetes, Proteinuria
- Trial name
- NCT00961207
- Testing
- Aliskiren
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Cook County Health
Diabetic Nephropathies
Add-on Pentoxifylline to Losartan Versus Increasing Dose of Losartan on NT-PRO BNP in Type 2 Diabetics With Nephropathy
This study was designed to assess the efficacy of adding pentoxifylline to losartan in comparison with increasing dose of losartan in type 2 diabetes patients with nephropathy.
- Trial name
- NCT03006952
- Testing
- Pentoxifylline, Losartan
- Where
- Iran
- Volunteers
- 59 people
- Sponsor
- Tehran University of Medical Sciences
Diabetic Nephropathy, Chronic Kidney Disease
Mycophenolate Mofetil, Carnitine and PDE5 Inhibitor, Three Potential Treatments for Resistant Proteinuria Slowing Diabetic Nephropathy Deterioration
Diabetes mellitus (DM) is a growing disease and it is a public health concern, and projections of its future effect are alarming. About one third of those affected will develop diabetic nephropathy at 20 years after diagnosis.
- Trial name
- Myridian (NCT01566006)
- Testing
- Mycophenolate Mofetil (MMF) ,phosphodiesterase 5 inhibitors , CARNITINE
- Where
- Israel
- Volunteers
- 80 people
- Sponsor
- The Nazareth Hospital, Israel
Type 2 Diabetes, Overt Diabetic Nephropathy
Effects of Rosiglitazone on Renal Hemodynamics and Proteinuria of Type 2 Diabetic Patients With Renal Insufficiency Due to Overt Diabetic Nephropathy
Objective: To evaluate how rosiglitazone does influence the renal plasma flow, the glomerular filtration rate and the degree of proteinuria in type 2 diabetic patients with renal insufficiency due to overt diabetic nephropathy.
- Trial name
- NCT00324675
- Testing
- Rosiglitazone
- Where
- Germany
- Volunteers
- 28 people
- Sponsor
- Technische Universität Dresden
Diabetic Nephropathy, Persistent Proteinuria With Type II Diabetes
Renal Denervation in Diabetic Nephropathy
The DERENEDIAB study is a proof-of-concept, multi-center, prospective, open, randomized, controlled study of the effectiveness of renal denervation in addition to standardized medical treatment compared to medical treatment alone…
- Trial name
- DERENEDIAB (NCT01588795)
- Testing
- Percutaneous renal denervation and TMNS, Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Kidney Insufficiency, Diabetes Mellitus
Plant Versus Animal Dietary Protein and the Effect on Proteinuria
The purpose of this study is to investigate if a diet high in plant protein improves kidney function in patients with kidney insufficiency and diabetes and/or hypertension and/or glomerulonephritis.
- Conditions
- Kidney Insufficiency, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
- Trial name
- NYPRO (NCT04058951)
- Testing
- High Animal Protein Diet (HAPD), High Plant Protein Diet (HPPD)
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Jens Rikardt Andersen
Chronic Kidney Disease, Diabetic Nephropathy
A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors
The study objective is to investigate the effects of three low doses of atrasentan on urinary albumin/creatinine ratio (UACR) levels in subjects with Type 2 diabetic nephropathy.
- Trial name
- NCT00920764
- Testing
- 0.25 mg Atrasentan QD, 0.75 mg Atrasentan QD, 1.75 mg Atrasentan QD
- Where
- 28 sites in United States, Puerto Rico
- Volunteers
- 92 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Chronic Kidney Diseases, Albuminuria
Diabetic Nephropathy in People With Diabetes. Prevalence and Predictive Factors
a prospective, observational, multi-center study with a cohort of 300 patients with Type 2 diabetes and macroalbuminuria. Prospectively we will collect kidney biopsies and analyse the transciptome of the kidney tissue and other…
- Conditions
- Chronic Kidney Diseases, Albuminuria, Diabetic Kidney Disease, Diabetic Nephropathies
- Trial name
- PRIMETIME2 (NCT04916132)
- Testing
- Kidney Biopsy
- Where
- 13 sites in Denmark
- Volunteers
- 300 people
- Sponsor
- Herlev Hospital
Type 2 Diabetes, Proteinuria
Improving Renal Complications in Adolescents With Type 2 Diabetes Through REsearch Cohort Study (National iCARE Study)
The overall aim of the project is to elucidate the primary bio-psycho-social (BPS) risk factors for albuminuria in youth with type 2 diabetes (T2D) and the mechanisms by which they cause renal injury. The Study aims include: 1.
- Conditions
- Type 2 Diabetes, Proteinuria, Stress, Nephropathy
- Trial name
- iCARE (NCT02818192)
- Where
- Canada
- Volunteers
- 500 people
- Sponsor
- University of Manitoba
Diabetic Nephropathy
Open Label Tolerability and Safety Study of KRX-101 in Australia, New Zealand, and Hong Kong
The purpose of this study is to assess the tolerability and safety of KRX-101 in treating persistent microalbuminuria in type 2 diabetic patients who are also being treated with stable, maximum tolerated doses of either ACE…
- Trial name
- NCT00462202
- Testing
- sulodexide
- Where
- Australia
- Volunteers
- 200 people
- Sponsor
- Keryx Biopharmaceuticals
Albuminuria
Effects of Amlodipine/Benazepril on Albuminuria in Hypertensive Patients With Type 2 Diabetes Mellitus
Type 2 diabetes mellitus is usually associated with high blood pressure, which is a risk factor for kidney disease. Aggressive blood pressure reduction is an important strategy to protect the kidney and reduce urinary protein…
- Trial name
- NCT00136773
- Testing
- amlodipine/benazepril
- Volunteers
- 332 people
- Sponsor
- Novartis
Type 2 Diabetes Mellitus, Proteinuria
Comparing the Renal Effect of Dipeptidyl-peptidase 4 Inhibitors and Sulfonylureas
Dipeptidyl peptidase 4 (DPP-4) inhibitors and sulfonylureas have been extensively used in the treatment of type 2 diabetes mellitus (T2DM).
- Trial name
- NCT03983551
- Testing
- Dipeptidyl Peptidase 4 Inhibitor, Sulfonylurea
- Volunteers
- 101 people
- Sponsor
- Changhua Christian Hospital